Literature DB >> 9644642

The prognostic significance of specific arterial lesions in acute renal allograft rejection.

V Nickeleit1, E C Vamvakas, M Pascual, B J Poletti, R B Colvin.   

Abstract

Diagnosis of allograft dysfunction relies on the assessment of arterial lesions. This study was designed to evaluate the prognostic significance of common specific vascular lesions in acute allograft rejection. Renal allograft biopsies (n = 111) with acute cellular rejection were scored for endarteritis, mononuclear cell adherence to endothelial cells, endothelial activation, fibrinoid necrosis, foam cells, and intimal fibrosis. These vascular lesions and other classic histologic features were correlated with outcome. Rejection with endarteritis (found in 54% of biopsies) was less responsive to steroid treatment than rejection without endarteritis, as judged by recovery of creatinine in 3 wk (P = 0.03). Larger numbers of sampled arteries improved the predictive accuracy. Sticking of mononuclear cells to endothelial cells also correlated with steroid resistance (P < 0.05). Rejection with or without endarteritis responded to OKT3/antithymocyte globulin treatment equally well (61% versus 65%, respectively). Rejection with fibrinoid arterial necrosis (4% of biopsies) did not respond to either steroids or antibodies (0%). One-year graft failure was 21% without endarteritis, 28% with endarteritis, and 100% with fibrinoid necrosis. Activated endothelial cells and interstitial hemorrhage were associated with endarteritis and graft failure (all P < 0.05). None of the other scored features had any statistically significant correlation with outcome. Thus, specific arterial lesions (endarteritis, fibrinoid necrosis, activated endothelial cells, mononuclear cell margination) and interstitial hemorrhage, but not the extent of the interstitial infiltrate or tubulitis, are correlated with response to antirejection therapy and/or 1-yr clinical outcome. Grading systems for therapeutic trials and clinical management should emphasize scoring of specific vascular lesions.

Entities:  

Mesh:

Year:  1998        PMID: 9644642     DOI: 10.1681/ASN.V971301

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  11 in total

1.  Neutralizing IL-6 reduces human arterial allograft rejection by allowing emergence of CD161+ CD4+ regulatory T cells.

Authors:  Birgit Fogal; Tai Yi; Chen Wang; Deepak A Rao; Amir Lebastchi; Sanjay Kulkarni; George Tellides; Jordan S Pober
Journal:  J Immunol       Date:  2011-11-14       Impact factor: 5.422

Review 2.  Interleukin 17 in vascular inflammation.

Authors:  Sibylle von Vietinghoff; Klaus Ley
Journal:  Cytokine Growth Factor Rev       Date:  2010-11-12       Impact factor: 7.638

Review 3.  Histopathological diagnosis of acute and chronic rejection in pediatric kidney transplantation.

Authors:  Verena Bröcker; Michael Mengel
Journal:  Pediatr Nephrol       Date:  2013-10-19       Impact factor: 3.714

4.  Clinical and pathological features of kidney transplant patients with concurrent polyomavirus nephropathy and rejection-associated endarteritis.

Authors:  Stephanie M McGregor; W James Chon; Lisa Kim; Anthony Chang; Shane M Meehan
Journal:  World J Transplant       Date:  2015-12-24

5.  The Clinical and Pathologic Phenotype of Antibody-Mediated Vascular Rejection Diagnosed Using Arterial C4d Immunoperoxidase.

Authors:  Brian J Nankivell; Meena Shingde; Chow H P'Ng; Ankit Sharma
Journal:  Kidney Int Rep       Date:  2022-05-05

6.  Treatment of acute kidney allograft rejection with a non-mitogenic CD3 antibody.

Authors:  R T Meijer; S Surachno; S L Yong; F J Bemelman; S Florquin; I J M Ten Berge; P T A Schellekens
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

7.  Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in Cynomolgus monkeys.

Authors:  R N Smith; T Kawai; S Boskovic; O Nadazdin; D H Sachs; A B Cosimi; R B Colvin
Journal:  Am J Transplant       Date:  2008-06-28       Impact factor: 8.086

8.  The role of angiotensin II type 1 receptor-activating antibodies in renal allograft vascular rejection.

Authors:  Duska Dragun
Journal:  Pediatr Nephrol       Date:  2007-03-06       Impact factor: 3.714

Review 9.  Banff Classification from 1991 to 2019. A Significant Contribution to Our Understanding and Reporting of Allograft Renal Biopsies.

Authors:  Swarnalata Gowrishankar
Journal:  Indian J Nephrol       Date:  2022-01-05

10.  Interleukin (IL)-1 promotes allogeneic T cell intimal infiltration and IL-17 production in a model of human artery rejection.

Authors:  Deepak A Rao; Raymond E Eid; Lingfeng Qin; Tai Yi; Nancy C Kirkiles-Smith; George Tellides; Jordan S Pober
Journal:  J Exp Med       Date:  2008-12-15       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.